Both nivolumab alone and in combination with ipilimumab resulted in a promising disease control rate in patients with relapsing malignant pleural mesothelioma (MPM), according to the results of Abstract LBA8507.
The EGFR tyrosine-kinase inhibitor gefitinib appears to offer a disease-free survival benefit over vinorelbine/cisplatin as adjuvant therapy in patients with non–small cell lung cancer with EGFR-activating mutation.
Researchers overseeing the trial at Roswell Park discuss the effectiveness of CIMAvax-EGF in NSCLC, the results of completed clinical trials in Cuba, and the long-term plans for additional testing of the vaccine.
Smoking not only causes many forms of cancer, but continued smoking by people with cancer and cancer survivors causes adverse health outcomes, including increased overall mortality, cancer-specific mortality, and risk for second primary cancer and is associated with increased treatment toxicity.
During the Education Session “Tobacco Cessation and CT Screening Recommendations for Patients With Lung Cancer,” to be held on June 4, experts will discuss strategies for implementing lung cancer screening programs.
How to best manage issues that are common in older patients with advanced non–small cell lung cancer will be the focus of the Education Session “Lung Cancer in the Older Population: Caring for the Whole Patient."
Results from a phase I study conducted in patients with relapsed or refractory metastatic disease revealed that single-agent treatment with the antibody-drug conjugate delivered a powerful blow to tumors bearing delta-like protein 3.
The NLST launched lung cancer screening, and since then, guidelines and recommendations have continued to evolve. Experts discussed rationale for lung screening, practical issues with screening implementation, and the enormous opportunity of addressing tobacco use during an Education Session.
The combination of the checkpoint inhibitor nivolumab with or without the anti–CTLA-4 ipilimumab resulted in durable objective responses for relapsed small cell lung cancer, regardless of platinum sensitivity or tumor PD-L1 expression.
Immune checkpoint inhibitors show promise in combating lung cancer and other malignancies by altering the tumor microenvironment and blocking the immune system evasion that allows cancers to grow and proliferate.